Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2006 3
2010 3
2011 5
2012 26
2013 80
2014 174
2015 545
2016 1145
2017 1927
2018 2521
2019 3215
2020 3933
2021 2255
Text availability
Article attribute
Article type
Publication date

Search Results

14,204 results
Results by year
Filters applied: . Clear all The following term was ignored: (
Page 1
Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y, Abu-Sbeih H, Wang Y. Tian Y, et al. Adv Exp Med Biol. 2018;995:159-164. doi: 10.1007/978-3-030-02505-2_8. Adv Exp Med Biol. 2018. PMID: 30539511 Review.
Immune checkpoint inhibitors (ICIs) have been increasingly used for multiple cancer types in the past decade. ICIs include CTLA-4 inhibitors (e.g., ipilimumab) and the PD-1 and PD-L1 inhibitors (e.g., nivolumab and pembrolizumab). ...
Immune checkpoint inhibitors (ICIs) have been increasingly used for multiple cancer types in the past decade. ICIs include CTLA-4 inh …
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Ferris RL, et al. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17. Oral Oncol. 2018. PMID: 29884413 Free PMC article. Clinical Trial.
METHODS: Patients with R/M SCCHN with tumor progression/recurrence within 6 months of platinum therapy were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator's choice (IC). Primary endpoint: overall survival (OS). ...Estimated OS rates at 18, 24, and …
METHODS: Patients with R/M SCCHN with tumor progression/recurrence within 6 months of platinum therapy were randomized 2:1 to nivolumab
The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin Q, Pei L, Cai F, Ma L, Yu Y. Chen R, et al. Discov Med. 2018 Oct;26(143):155-166. Discov Med. 2018. PMID: 30586539 Free article. Review.
Only the pembrolizumab approval is limited to the PD-L1-positive NSCLC; both nivolumab and atezolizumab can be currently used irrespective of tumor PD-L1 expression. Biomarkers for the response to PD-1/PD-LI checkpoint inhibitors beyond PD-L1 expressio …
Only the pembrolizumab approval is limited to the PD-L1-positive NSCLC; both nivolumab and atezolizumab can be currently used …
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Van Allen EM, et al. Among authors: weide b. Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10. Science. 2015. PMID: 26359337 Free PMC article.
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response t …
Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable c …
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Xu C, et al. BMJ. 2018 Nov 8;363:k4226. doi: 10.1136/bmj.k4226. BMJ. 2018. PMID: 30409774 Free PMC article.
The general safety of ICI drugs ranked from high to low for all adverse events was as follows: atezolizumab (probability 76%, pooled incidence 66.4%), nivolumab (56%, 71.8%), pembrolizumab (55%, 75.1%), ipilimumab (55%, 86.8%), and tremelimumab (54%, not appl …
The general safety of ICI drugs ranked from high to low for all adverse events was as follows: atezolizumab (probability 76%, pooled inciden …
Nivolumab plus ipilimumab in non-small-cell lung cancer.
Reck M, Borghaei H, O'Byrne KJ. Reck M, et al. Future Oncol. 2019 Jul;15(19):2287-2302. doi: 10.2217/fon-2019-0031. Epub 2019 May 8. Future Oncol. 2019. PMID: 31066582 Free article. Review.
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single agents and in combination. In this Review, we examine the potential role of dual immune checkpoi
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respective
Nivolumab for the treatment of hepatocellular carcinoma.
Finkelmeier F, Waidmann O, Trojan J. Finkelmeier F, et al. Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22. Expert Rev Anticancer Ther. 2018. PMID: 30304963 Review.
In 2014, the US Food and Drug Administration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully human immunoglobulin G4 anti-PD-1 monoclonal antibody which is approved for mu …
In 2014, the US Food and Drug Administration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by …
Nivolumab for the treatment of colorectal cancer.
Smith KM, Desai J. Smith KM, et al. Expert Rev Anticancer Ther. 2018 Jul;18(7):611-618. doi: 10.1080/14737140.2018.1480942. Epub 2018 Jun 11. Expert Rev Anticancer Ther. 2018. PMID: 29792730 Review.
Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly. ...The current review will summarize the clinical evidence of checkpoint inhibitors in meta …
Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had …
Immunotherapy for Head and Neck Cancer.
Sim F, Leidner R, Bell RB. Sim F, et al. Oral Maxillofac Surg Clin North Am. 2019 Feb;31(1):85-100. doi: 10.1016/j.coms.2018.09.002. Oral Maxillofac Surg Clin North Am. 2019. PMID: 30449528 Review.
An understanding of this mechanism provides the basis for improved therapies and outcomes for patients. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. ...
An understanding of this mechanism provides the basis for improved therapies and outcomes for patients. Through the tumor's influence …
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
Shen X, Zhao B. Shen X, et al. BMJ. 2018 Sep 10;362:k3529. doi: 10.1136/bmj.k3529. BMJ. 2018. PMID: 30201790 Free PMC article.
REVIEW METHODS: Studies of PD-1 or PD-L1 inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) that had available hazard ratios for death based on PD-L1 positivity or negativity were included. ...This finding suggests that PD-L1 expression st …
REVIEW METHODS: Studies of PD-1 or PD-L1 inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) that ha …
14,204 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page